Together, these results suggest that BAY1082439 treatment may convert the PTEN-loss induced cancer cell-intrinsic immuno-suppression to immuno-stimulation by upregulating IFNα and IFNγ pathways, increasing cancer cell antigen-presentation, and releasing T cell attractive chemokines. The gene discussed is PTEN; the disease is cancer.